Last reviewed · How we verify
Erenumab 140 mg — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
Erenumab 140 mg (Erenumab 140 mg) — Amgen.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Erenumab 140 mg TARGET | Erenumab 140 mg | Amgen | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Erenumab 140 mg CI watch — RSS
- Erenumab 140 mg CI watch — Atom
- Erenumab 140 mg CI watch — JSON
- Erenumab 140 mg alone — RSS
Cite this brief
Drug Landscape (2026). Erenumab 140 mg — Competitive Intelligence Brief. https://druglandscape.com/ci/erenumab-140-mg. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab